Other Events ·
On June 26, 2026, Viridian Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved…
VRDNViridian Therapeutics, Inc.\DE
On June 26, 2026, Viridian Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED) regardless of activity or duration. Lumvoa is the first approved treatment for TED with labeling that includes data for both active and chronic TED. Viridian plans to launch Lumvoa immediately. Viridian Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions for ophthalmology and immunology.